Hyderabad-based Aragen Life Sciences is preparing an IPO to raise up to ₹3,500 crore. The funds will be used to reduce debt and expand its research and manufacturing facilities to meet rising global demand for outsourced drug development services.
Aragen Life Sciences, a contract research and manufacturing organization based in Hyderabad, is moving ahead with plans for an Initial Public Offering (IPO). The company expects to raise approximately ₹3,500 crore through this public issue, which will consist of a mix of new shares and a sale of existing holdings. The company is expected to file its preliminary paperwork, known as the Draft Red Herring Prospectus, with the market regulator in the near future.
Debt Reduction and Capacity Expansion
A significant portion of the money raised from the IPO is planned for debt repayment. By lowering its outstanding borrowings, the company aims to improve its financial health. The remaining funds are intended for capital spending on expansion projects. Specifically, the company is looking to increase its research and manufacturing capacities to handle a larger volume of projects. This comes as the demand for contract research, development, and manufacturing organization (CRDMO) services continues to grow globally, with pharmaceutical and biotechnology companies looking for reliable partners for drug discovery and API synthesis.
Market Context and Investor Backing
Aragen currently provides services to over 400 clients across various sectors, including agrochemicals and animal health. It operates multiple facilities in India across cities like Hyderabad, Bengaluru, Pune, and Visakhapatnam, as well as a specialized biologics research center in California. The company has attracted significant private equity interest, with major backers such as Goldman Sachs and Quadria Capital. In early 2025, Quadria Capital acquired a minority stake in the business at a valuation of approximately $1.4 billion.
Opportunities and Risks in the CRDMO Sector
The Indian CRDMO sector is currently seeing increased attention due to India’s cost advantages and specialized scientific talent. Projections suggest that this industry in India could see long-term growth as global firms shift more research and production tasks to specialized providers. However, for investors, the success of such an expansion will depend on the company's ability to execute these new projects without significant delays or cost increases. Additionally, because the CRDMO business is highly dependent on long-term client contracts, the company’s future revenue and profit margins will be closely tied to its ability to maintain these relationships and manage the competitive pricing pressure that is common in global drug development services. Investors will likely look for updates on the final valuation, the specific debt-to-equity targets post-IPO, and the timeline for the new manufacturing units to become operational.